UBS Maintains a 'Neutral' on Vertex (VRTX); Watching and Waiting
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Price: $505.75 -2.07%
Rating Summary:
38 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
38 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
UBS maintains a 'Neutral' on Vertex (NASDAQ: VRTX) price target slashes from $47 to $35.
UBS analyst says, "Stock should work after [1] expectations are re-set, and [2] Rx trends drop: Following extensive due diligence at the recent AASLD Liver Meeting, we are retaining our Neutral rating but lowering our PT to $35. We stay Neutral for now, as we think an overhang will persist until Incivek Rx trends peak (1H12e). However, we expect a bull case to emerge at some point in 2012 from Street HCV numbers having come down, resetting expectations, as well as from improved visibility into shareholder-friendly strategies and ahead of data in cystic fibrosis (CF) mid-2012e."
UBS raises FY11 EPS estimate from $0.50 to $0.54, but lowers FY12 from $4.70 to $4.60.
For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.
Shares of Vertex closed at $31.98 yesterday.
UBS analyst says, "Stock should work after [1] expectations are re-set, and [2] Rx trends drop: Following extensive due diligence at the recent AASLD Liver Meeting, we are retaining our Neutral rating but lowering our PT to $35. We stay Neutral for now, as we think an overhang will persist until Incivek Rx trends peak (1H12e). However, we expect a bull case to emerge at some point in 2012 from Street HCV numbers having come down, resetting expectations, as well as from improved visibility into shareholder-friendly strategies and ahead of data in cystic fibrosis (CF) mid-2012e."
UBS raises FY11 EPS estimate from $0.50 to $0.54, but lowers FY12 from $4.70 to $4.60.
For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.
Shares of Vertex closed at $31.98 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital on Vertex (VRTX): 'SION Overhang Cleared; We Would Remain Buyers'
- Vertex Pharma (VRTX) Added to BofA US 1 List
- JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
